Bioequivalence studies are an essential component in the development and approval of generic pharmaceutical products, ensuring that they perform similarly to their reference counterparts. These ...
Table III. Pharmacokinetic parameters for rebamipide following oral administration of granules or a tablet at a dose of 100mg in 27 healthy adult male volunteers [mean (SD)] ...
These factors could provide a scientific basis for consistency evaluations of the quality and efficacy of insulin biosimilars, study authors wrote. Factors that may affect the bioequivalence of test ...
LOS ALTOS, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today ...
Health ministry amends NDCT Rules to enable faster commencement of BA/BE studies: Gireesh Babu, New Delhi Thursday, January 29, 2026, 08:00 Hrs [IST] In an effort to enable faster ...
LAPIX has completed a bioequivalence study in healthy human volunteers evaluating the pharmacokinetics and exposure profile of the new solid-dose capsule relative to the Phase I liquid solution. The ...
On Friday, Eton Pharmaceuticals, Inc (NASDAQ:ETON) revealed results from its bioequivalence study of ET-600, a proprietary, patented oral solution of desmopressin under development for central ...
LOS ALTOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics (UNCY), Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” ...
VANCOUVER, BC/ ACCESS Newswire/ April 23, 2025/ BioNxt Solutions Inc., a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human ...
BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, is pleased to announce the launch ...
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results